techtimes.com
· Jul 15, 2026 4:46 PM EDT
Not market news
AstraZeneca Pays $600M for Oral Pill That Beat Chemo in Rare Lung Cancer
Sunvozertinib lung cancer treatment hit a milestone as AstraZeneca paid $600M upfront for Zegfrovy, the first oral pill to beat chemotherapy in a Phase III trial for EGFR exon 20 insertion NSCLC — extending progression-free survival to 10.3 months vs 7.5 months on chemo. Zegfrovy now positions as
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief